$PHGE·8-K

BiomX Inc. · Mar 2, 4:05 PM ET

Compare

BiomX Inc. 8-K

Research Summary

AI-generated summary

Updated

BiomX Inc. Reports Executive Resignations; Appoints New CFO

What Happened

  • BiomX Inc. announced several senior departures and a CFO appointment. On February 24, 2026, Marina Wolfson resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and Dr. Merav Bassan resigned as Chief Development Officer, both effective that date. On February 25, 2026, directors Greg Merril, Edward Williams, and Susan Blum each resigned from the Board, effective February 25, 2026. None of these resignations resulted from any disagreement with the Company.
  • To fill the CFO vacancy, the Board appointed David Rokach (age 58) as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective February 27, 2026. Mr. Rokach’s background includes roles at Nukkleus Inc., Newcom Finance (2017–2025), Granit Investment Company (2021–2023), and independent consulting since 2014. The Company reported no related-party arrangements or family relationships requiring disclosure.

Key Details

  • Executive resignations: Marina Wolfson and Dr. Merav Bassan — effective February 24, 2026.
  • Board resignations: Greg Merril, Edward Williams, Susan Blum — effective February 25, 2026.
  • New CFO: David Rokach appointed February 27, 2026 (age 58); experience in finance, investment management, and public company governance.
  • Special Meeting adjourned for lack of quorum on February 25, 2026; reconvened virtually on March 11, 2026 at 8:00 a.m. ET at www.virtualshareholdermeeting.com/PHGE2026SM. Record date for voting remains February 3, 2026. No changes to the proposals.

Why It Matters

  • Leadership and board changes are material governance events that can affect company oversight, financial reporting continuity, and investor confidence. The appointment of an experienced finance executive aims to restore financial leadership after the CFO departure.
  • The adjournment of the Special Meeting delays stockholder votes on the proposals in the February 13, 2026 proxy, which could postpone outcomes investors are watching. Investors should monitor any further governance announcements and the results of the reconvened meeting.

Loading document...